Radiopharm Theranostics Files 6-K for January 2025
Ticker: RDPTF · Form: 6-K · Filed: Jan 30, 2025 · CIK: 1949257
| Field | Detail |
|---|---|
| Company | Radiopharm Theranostics Ltd (RDPTF) |
| Form Type | 6-K |
| Filed Date | Jan 30, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, foreign-private-issuer, routine-update
TL;DR
Radiopharm Theranostics filed its monthly 6-K update with the SEC on Jan 30, 2025.
AI Summary
Radiopharm Theranostics Limited filed a Form 6-K on January 30, 2025, reporting information for the month of January 2025. The company is a foreign private issuer and is providing updates as required by the SEC. The filing indicates the company is incorporated in Australia and its principal executive office is located in Carlton South, Victoria.
Why It Matters
This filing provides routine updates from a foreign private issuer, offering transparency on ongoing corporate activities and compliance with SEC regulations.
Risk Assessment
Risk Level: low — This is a routine filing by a foreign private issuer and does not contain significant new financial or operational information that would immediately impact risk.
Key Numbers
- 001-41621 — SEC File Number (Identifies the company's filing with the SEC.)
Key Players & Entities
- Radiopharm Theranostics Limited (company) — Registrant
- 001-41621 (dollar_amount) — Commission File Number
- January 2025 (date) — Reporting Period
- Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (company) — Principal executive office address
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that provides information which the issuer makes or is required to make public pursuant to the laws of the issuer's home country, or which it furnishes or makes public to its security holders.
What period does this specific 6-K filing cover?
This Form 6-K filing covers the month of January 2025.
Is Radiopharm Theranostics Limited a US-based company?
No, Radiopharm Theranostics Limited is a foreign private issuer with its principal executive office located in Australia.
What is the company's SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Does Radiopharm Theranostics file an annual report on Form 20-F?
Yes, the filing indicates that the registrant files or will file annual reports under cover of Form 20-F.
Filing Stats: 316 words · 1 min read · ~1 pages · Grade level 19.3 · Accepted 2025-01-30 08:00:09
Filing Documents
- ea0229224-6k_radio.htm (6-K) — 13KB
- ea022922401ex99-1_radio.htm (EX-99.1) — 141KB
- ex99-1_001.jpg (GRAPHIC) — 127KB
- ex99-1_002.jpg (GRAPHIC) — 8KB
- ex99-1_003.jpg (GRAPHIC) — 9KB
- ex99-1_004.jpg (GRAPHIC) — 342KB
- 0001213900-25-008082.txt ( ) — 824KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on January 30, 2025 titled: - “Quarterly Activities/Appendix 4C Cash Flow Report” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Quarterly Activities/Appendix 4C Cash Flow Report 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: January 30, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3